Royalty Pharma to launch $800 million term loan B on Tuesday

By Sara Rosenberg

New York, April 29 – Royalty Pharma will hold a lender meeting on Tuesday to launch an $800 million seven-year incremental term loan B, according to a market source.

Bank of America Merrill Lynch is the left lead on the deal.

Proceeds will be used to fund the potential acquisition of a royalty stream in Keytruda, a medicine that may treat certain cancers by working with the immune system.

Other funds for the transaction will come from a $200 million term loan A and cash on hand.

Royalty Pharma is a New York-based acquirer of royalty interests in marketed and late-stage biopharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.